TY - T1的规范数据为多个呼吸冲刷的结果在学龄白人孩子摩根富林明——欧洲呼吸杂志乔-和J欧元做10.1183/13993003.01302 -2019 SP - 1901302 AU Pinelopi Anagnostopoulou AU -菲利普·Latzin盟蕾妮·延森盟Mirjam斯塔尔AU -阿拉娜哈珀盟苏菲Yammine盟Jakob Usemann AU -瑞秋大肠Foong盟本Spycher AU -格雷厄姆·l·霍尔盟Florian歌手盟Sanja Stanojevic AU -马库斯商场盟Felix Ratjen AU -凯瑟琳·a·拉姆齐Y1 - 2019/01/01 UR - //www.qdcxjkg.com/content/early/2019/12/12/13993003.01302 - 2019. -抽象N2 -背景氮多个呼吸冲刷(N2MBW)技术正越来越多地用于评估通风的程度不均匀性在学龄儿童肺病。然而,参考价值健康儿童目前不可用。本研究的目的是为N2MBW生成引用值结果在一群健康的白人学龄儿童。方法N2MBW数据从健康白种人学龄儿童6 - 18年收集从四个经验丰富的中心。使用超声波流量计进行测量(Exhalyzer D, Eco医生AG) Duernten,瑞士)和商业软件进行了分析(Spiroware, 3.2.1之上,Eco医生AG)。规范性价值观和正常的上限为肺间隙生成指数在2.5% (LCI2.5%)和5% (LCI5%),时刻比率(M1 / M0和M2 / M0),和一个预测方程生成的功能余气量(FRC)。四百八十五年试验结果从180年健康白种人从6到18岁的儿童被用于分析。虽然LCI随着年龄的增加,这种增加是可以忽略不计(LCI2.5% 0.04户/年),因此固定上限这个年龄段的正常的定义。这些限制LCI2.5% 7.91, 5.73 LCI5%, 1.75 M1 / mo,分别为6.15平方米/ mo。身高和体重是FRC的独立预测指标。结论我们报告引用值N2MBW结果在商用超声波流量计测量设备(Exhalyzer D, Eco医生AG)、Duernten、瑞士)在健康学龄儿童,让儿童通风分布结果和FRC的准确解释与肺部疾病。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。 It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Anagnostopoulou has nothing to disclose.Conflict of interest: Dr. Latzin reports personal fees from Gilead, personal fees from Novartis, personal fees from Polyphor, personal fees from Santhera, personal fees from Schwabe, personal fees from Vertex, personal fees from Vifor, personal fees from Zambon, grants from Vertex, outside the submitted work.Conflict of interest: R. Jensen has nothing to disclose.Conflict of interest: Dr. Stahl reports personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Harper has nothing to disclose.Conflict of interest: Dr. Yammine has nothing to disclose.Conflict of interest: Dr. Usemann has nothing to disclose.Conflict of interest: Dr. Foong has nothing to disclose.Conflict of interest: Dr. Spycher has nothing to disclose.Conflict of interest: Dr. Hall reports grants from NHMRC, Australia and USA CF Foundation, and non-financial support from ndd, during the conduct of the study.Conflict of interest: Dr. Singer reports personal fees from Vertex, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Stanojevic has nothing to disclose.Conflict of interest: Dr. Mall reports grants from German Federal Ministry of Education and Research , grants from Einstein Foundation Berlin, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Ratjen reports grants and personal fees from Vertex, personal fees from Novartis, personal fees from Bayer, personal fees from Roche, personal fees from Genetech, outside the submitted work.Conflict of interest: Dr. Ramsey has nothing to disclose. ER -